A consistent biological barrier that stops the immune system from making the antibodies most needed to protect the nose and ...
Higher vaccine efficacy was observed with mRNA-1283 vs mRNA-1273.222 in individuals aged 65 years and older. A phase 3 trial evaluating Moderna’s next-generation COVID-19 vaccine, mRNA-1283, met its ...
Current data reveals no significant differences in the antibody responses to the XBB.1 variant of SARS-CoV-2 between the BA.4/BA.5 and BA.1 vaccines. While the precise formulation of future vaccine ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results